Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 6Advanced Solid Tumours 5Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Uterine Cervical Neoplasms 3Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple-negative Metastatic Breast Cancer 1Tongue Neoplasms 1Thyroid Neoplasms 1Rhabdomyosarcoma 1

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroectodermal Tumors, Primitive × adavosertib × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡